Discovery of the First Selective M 4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy

Nonselective antagonists of muscarinic acetylcholine receptors (mAChRs) that broadly inhibit all five mAChR subtypes provide an efficacious treatment for some movement disorders, including Parkinson's disease and dystonia. Despite their efficacy in these and other central nervous system disorde...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS pharmacology & translational science 2021-08, Vol.4 (4), p.1306-1321
Hauptverfasser: Moehle, Mark S, Bender, Aaron M, Dickerson, Jonathan W, Foster, Daniel J, Qi, Aidong, Cho, Hyekyung P, Donsante, Yuping, Peng, Weimin, Bryant, Zoey, Stillwell, Kaylee J, Bridges, Thomas M, Chang, Sichen, Watson, Katherine J, O'Neill, Jordan C, Engers, Julie L, Peng, Li, Rodriguez, Alice L, Niswender, Colleen M, Lindsley, Craig W, Hess, Ellen J, Conn, P Jeffrey, Rook, Jerri M
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1321
container_issue 4
container_start_page 1306
container_title ACS pharmacology & translational science
container_volume 4
creator Moehle, Mark S
Bender, Aaron M
Dickerson, Jonathan W
Foster, Daniel J
Qi, Aidong
Cho, Hyekyung P
Donsante, Yuping
Peng, Weimin
Bryant, Zoey
Stillwell, Kaylee J
Bridges, Thomas M
Chang, Sichen
Watson, Katherine J
O'Neill, Jordan C
Engers, Julie L
Peng, Li
Rodriguez, Alice L
Niswender, Colleen M
Lindsley, Craig W
Hess, Ellen J
Conn, P Jeffrey
Rook, Jerri M
description Nonselective antagonists of muscarinic acetylcholine receptors (mAChRs) that broadly inhibit all five mAChR subtypes provide an efficacious treatment for some movement disorders, including Parkinson's disease and dystonia. Despite their efficacy in these and other central nervous system disorders, antimuscarinic therapy has limited utility due to severe adverse effects that often limit their tolerability by patients. Recent advances in understanding the roles that each mAChR subtype plays in disease pathology suggest that highly selective ligands for individual subtypes may underlie the antiparkinsonian and antidystonic efficacy observed with the use of nonselective antimuscarinic therapeutics. Our recent work has indicated that the M muscarinic acetylcholine receptor has several important roles in opposing aberrant neurotransmitter release, intracellular signaling pathways, and brain circuits associated with movement disorders. This raises the possibility that selective antagonists of M may recapitulate the efficacy of nonselective antimuscarinic therapeutics and may decrease or eliminate the adverse effects associated with these drugs. However, this has not been directly tested due to lack of selective antagonists of M . Here, we utilize genetic mAChR knockout animals in combination with nonselective mAChR antagonists to confirm that the M receptor activation is required for the locomotor-stimulating and antiparkinsonian efficacy in rodent models. We also report the synthesis, discovery, and characterization of the first-in-class selective M antagonists VU6013720, VU6021302, and VU6021625 and confirm that these optimized compounds have antiparkinsonian and antidystonic efficacy in pharmacological and genetic models of movement disorders.
doi_str_mv 10.1021/acsptsci.0c00162
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_acsptsci_0c00162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>34423268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c196t-e2935385683911e2aeb6e66da7121b737a45cf1ff4d9b10e453b469b0a16003b3</originalsourceid><addsrcrecordid>eNpNkM1OAjEUhRujEYLsXZm-ANqfmc7MkiCoCcTEv-2k07mV6tBO2oKZV_CpBQHj6p7ck-8sPoQuKbmmhNEbqUIbgzLXRBFCBTtBfZZm6aigJD_9l3toGMIHIYQRwmlBzlGPJwnjTOR99H1rgnIb8B12Gscl4JnxIeJnaEBFswG8wAlerIOS3lij8FhB7Bq1dI2xgJ9AQRudx2Mb5buzJsSAv0xcYmPxm9m4XWFa6T-NDdtaWixt_fusuxDdbnGqtVFSdRfoTMsmwPBwB-h1Nn2Z3I_mj3cPk_F8pGgh4ghYwVOepyLnBaXAJFQChKhlRhmtMp7JJFWaap3URUUJJCmvElFURFKxFVDxASL7XeVdCB502Xqzkr4rKSl3Zsuj2fJgdotc7ZF2Xa2g_gOOHvkPStx4kA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Discovery of the First Selective M 4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy</title><source>PubMed Central</source><source>American Chemical Society Journals</source><creator>Moehle, Mark S ; Bender, Aaron M ; Dickerson, Jonathan W ; Foster, Daniel J ; Qi, Aidong ; Cho, Hyekyung P ; Donsante, Yuping ; Peng, Weimin ; Bryant, Zoey ; Stillwell, Kaylee J ; Bridges, Thomas M ; Chang, Sichen ; Watson, Katherine J ; O'Neill, Jordan C ; Engers, Julie L ; Peng, Li ; Rodriguez, Alice L ; Niswender, Colleen M ; Lindsley, Craig W ; Hess, Ellen J ; Conn, P Jeffrey ; Rook, Jerri M</creator><creatorcontrib>Moehle, Mark S ; Bender, Aaron M ; Dickerson, Jonathan W ; Foster, Daniel J ; Qi, Aidong ; Cho, Hyekyung P ; Donsante, Yuping ; Peng, Weimin ; Bryant, Zoey ; Stillwell, Kaylee J ; Bridges, Thomas M ; Chang, Sichen ; Watson, Katherine J ; O'Neill, Jordan C ; Engers, Julie L ; Peng, Li ; Rodriguez, Alice L ; Niswender, Colleen M ; Lindsley, Craig W ; Hess, Ellen J ; Conn, P Jeffrey ; Rook, Jerri M</creatorcontrib><description>Nonselective antagonists of muscarinic acetylcholine receptors (mAChRs) that broadly inhibit all five mAChR subtypes provide an efficacious treatment for some movement disorders, including Parkinson's disease and dystonia. Despite their efficacy in these and other central nervous system disorders, antimuscarinic therapy has limited utility due to severe adverse effects that often limit their tolerability by patients. Recent advances in understanding the roles that each mAChR subtype plays in disease pathology suggest that highly selective ligands for individual subtypes may underlie the antiparkinsonian and antidystonic efficacy observed with the use of nonselective antimuscarinic therapeutics. Our recent work has indicated that the M muscarinic acetylcholine receptor has several important roles in opposing aberrant neurotransmitter release, intracellular signaling pathways, and brain circuits associated with movement disorders. This raises the possibility that selective antagonists of M may recapitulate the efficacy of nonselective antimuscarinic therapeutics and may decrease or eliminate the adverse effects associated with these drugs. However, this has not been directly tested due to lack of selective antagonists of M . Here, we utilize genetic mAChR knockout animals in combination with nonselective mAChR antagonists to confirm that the M receptor activation is required for the locomotor-stimulating and antiparkinsonian efficacy in rodent models. We also report the synthesis, discovery, and characterization of the first-in-class selective M antagonists VU6013720, VU6021302, and VU6021625 and confirm that these optimized compounds have antiparkinsonian and antidystonic efficacy in pharmacological and genetic models of movement disorders.</description><identifier>ISSN: 2575-9108</identifier><identifier>EISSN: 2575-9108</identifier><identifier>DOI: 10.1021/acsptsci.0c00162</identifier><identifier>PMID: 34423268</identifier><language>eng</language><publisher>United States</publisher><ispartof>ACS pharmacology &amp; translational science, 2021-08, Vol.4 (4), p.1306-1321</ispartof><rights>2021 American Chemical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c196t-e2935385683911e2aeb6e66da7121b737a45cf1ff4d9b10e453b469b0a16003b3</citedby><cites>FETCH-LOGICAL-c196t-e2935385683911e2aeb6e66da7121b737a45cf1ff4d9b10e453b469b0a16003b3</cites><orcidid>0000-0002-8023-1313 ; 0000-0003-0168-1445 ; 0000-0002-5225-354X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2765,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34423268$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moehle, Mark S</creatorcontrib><creatorcontrib>Bender, Aaron M</creatorcontrib><creatorcontrib>Dickerson, Jonathan W</creatorcontrib><creatorcontrib>Foster, Daniel J</creatorcontrib><creatorcontrib>Qi, Aidong</creatorcontrib><creatorcontrib>Cho, Hyekyung P</creatorcontrib><creatorcontrib>Donsante, Yuping</creatorcontrib><creatorcontrib>Peng, Weimin</creatorcontrib><creatorcontrib>Bryant, Zoey</creatorcontrib><creatorcontrib>Stillwell, Kaylee J</creatorcontrib><creatorcontrib>Bridges, Thomas M</creatorcontrib><creatorcontrib>Chang, Sichen</creatorcontrib><creatorcontrib>Watson, Katherine J</creatorcontrib><creatorcontrib>O'Neill, Jordan C</creatorcontrib><creatorcontrib>Engers, Julie L</creatorcontrib><creatorcontrib>Peng, Li</creatorcontrib><creatorcontrib>Rodriguez, Alice L</creatorcontrib><creatorcontrib>Niswender, Colleen M</creatorcontrib><creatorcontrib>Lindsley, Craig W</creatorcontrib><creatorcontrib>Hess, Ellen J</creatorcontrib><creatorcontrib>Conn, P Jeffrey</creatorcontrib><creatorcontrib>Rook, Jerri M</creatorcontrib><title>Discovery of the First Selective M 4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy</title><title>ACS pharmacology &amp; translational science</title><addtitle>ACS Pharmacol Transl Sci</addtitle><description>Nonselective antagonists of muscarinic acetylcholine receptors (mAChRs) that broadly inhibit all five mAChR subtypes provide an efficacious treatment for some movement disorders, including Parkinson's disease and dystonia. Despite their efficacy in these and other central nervous system disorders, antimuscarinic therapy has limited utility due to severe adverse effects that often limit their tolerability by patients. Recent advances in understanding the roles that each mAChR subtype plays in disease pathology suggest that highly selective ligands for individual subtypes may underlie the antiparkinsonian and antidystonic efficacy observed with the use of nonselective antimuscarinic therapeutics. Our recent work has indicated that the M muscarinic acetylcholine receptor has several important roles in opposing aberrant neurotransmitter release, intracellular signaling pathways, and brain circuits associated with movement disorders. This raises the possibility that selective antagonists of M may recapitulate the efficacy of nonselective antimuscarinic therapeutics and may decrease or eliminate the adverse effects associated with these drugs. However, this has not been directly tested due to lack of selective antagonists of M . Here, we utilize genetic mAChR knockout animals in combination with nonselective mAChR antagonists to confirm that the M receptor activation is required for the locomotor-stimulating and antiparkinsonian efficacy in rodent models. We also report the synthesis, discovery, and characterization of the first-in-class selective M antagonists VU6013720, VU6021302, and VU6021625 and confirm that these optimized compounds have antiparkinsonian and antidystonic efficacy in pharmacological and genetic models of movement disorders.</description><issn>2575-9108</issn><issn>2575-9108</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpNkM1OAjEUhRujEYLsXZm-ANqfmc7MkiCoCcTEv-2k07mV6tBO2oKZV_CpBQHj6p7ck-8sPoQuKbmmhNEbqUIbgzLXRBFCBTtBfZZm6aigJD_9l3toGMIHIYQRwmlBzlGPJwnjTOR99H1rgnIb8B12Gscl4JnxIeJnaEBFswG8wAlerIOS3lij8FhB7Bq1dI2xgJ9AQRudx2Mb5buzJsSAv0xcYmPxm9m4XWFa6T-NDdtaWixt_fusuxDdbnGqtVFSdRfoTMsmwPBwB-h1Nn2Z3I_mj3cPk_F8pGgh4ghYwVOepyLnBaXAJFQChKhlRhmtMp7JJFWaap3URUUJJCmvElFURFKxFVDxASL7XeVdCB502Xqzkr4rKSl3Zsuj2fJgdotc7ZF2Xa2g_gOOHvkPStx4kA</recordid><startdate>20210813</startdate><enddate>20210813</enddate><creator>Moehle, Mark S</creator><creator>Bender, Aaron M</creator><creator>Dickerson, Jonathan W</creator><creator>Foster, Daniel J</creator><creator>Qi, Aidong</creator><creator>Cho, Hyekyung P</creator><creator>Donsante, Yuping</creator><creator>Peng, Weimin</creator><creator>Bryant, Zoey</creator><creator>Stillwell, Kaylee J</creator><creator>Bridges, Thomas M</creator><creator>Chang, Sichen</creator><creator>Watson, Katherine J</creator><creator>O'Neill, Jordan C</creator><creator>Engers, Julie L</creator><creator>Peng, Li</creator><creator>Rodriguez, Alice L</creator><creator>Niswender, Colleen M</creator><creator>Lindsley, Craig W</creator><creator>Hess, Ellen J</creator><creator>Conn, P Jeffrey</creator><creator>Rook, Jerri M</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-8023-1313</orcidid><orcidid>https://orcid.org/0000-0003-0168-1445</orcidid><orcidid>https://orcid.org/0000-0002-5225-354X</orcidid></search><sort><creationdate>20210813</creationdate><title>Discovery of the First Selective M 4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy</title><author>Moehle, Mark S ; Bender, Aaron M ; Dickerson, Jonathan W ; Foster, Daniel J ; Qi, Aidong ; Cho, Hyekyung P ; Donsante, Yuping ; Peng, Weimin ; Bryant, Zoey ; Stillwell, Kaylee J ; Bridges, Thomas M ; Chang, Sichen ; Watson, Katherine J ; O'Neill, Jordan C ; Engers, Julie L ; Peng, Li ; Rodriguez, Alice L ; Niswender, Colleen M ; Lindsley, Craig W ; Hess, Ellen J ; Conn, P Jeffrey ; Rook, Jerri M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c196t-e2935385683911e2aeb6e66da7121b737a45cf1ff4d9b10e453b469b0a16003b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moehle, Mark S</creatorcontrib><creatorcontrib>Bender, Aaron M</creatorcontrib><creatorcontrib>Dickerson, Jonathan W</creatorcontrib><creatorcontrib>Foster, Daniel J</creatorcontrib><creatorcontrib>Qi, Aidong</creatorcontrib><creatorcontrib>Cho, Hyekyung P</creatorcontrib><creatorcontrib>Donsante, Yuping</creatorcontrib><creatorcontrib>Peng, Weimin</creatorcontrib><creatorcontrib>Bryant, Zoey</creatorcontrib><creatorcontrib>Stillwell, Kaylee J</creatorcontrib><creatorcontrib>Bridges, Thomas M</creatorcontrib><creatorcontrib>Chang, Sichen</creatorcontrib><creatorcontrib>Watson, Katherine J</creatorcontrib><creatorcontrib>O'Neill, Jordan C</creatorcontrib><creatorcontrib>Engers, Julie L</creatorcontrib><creatorcontrib>Peng, Li</creatorcontrib><creatorcontrib>Rodriguez, Alice L</creatorcontrib><creatorcontrib>Niswender, Colleen M</creatorcontrib><creatorcontrib>Lindsley, Craig W</creatorcontrib><creatorcontrib>Hess, Ellen J</creatorcontrib><creatorcontrib>Conn, P Jeffrey</creatorcontrib><creatorcontrib>Rook, Jerri M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>ACS pharmacology &amp; translational science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moehle, Mark S</au><au>Bender, Aaron M</au><au>Dickerson, Jonathan W</au><au>Foster, Daniel J</au><au>Qi, Aidong</au><au>Cho, Hyekyung P</au><au>Donsante, Yuping</au><au>Peng, Weimin</au><au>Bryant, Zoey</au><au>Stillwell, Kaylee J</au><au>Bridges, Thomas M</au><au>Chang, Sichen</au><au>Watson, Katherine J</au><au>O'Neill, Jordan C</au><au>Engers, Julie L</au><au>Peng, Li</au><au>Rodriguez, Alice L</au><au>Niswender, Colleen M</au><au>Lindsley, Craig W</au><au>Hess, Ellen J</au><au>Conn, P Jeffrey</au><au>Rook, Jerri M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of the First Selective M 4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy</atitle><jtitle>ACS pharmacology &amp; translational science</jtitle><addtitle>ACS Pharmacol Transl Sci</addtitle><date>2021-08-13</date><risdate>2021</risdate><volume>4</volume><issue>4</issue><spage>1306</spage><epage>1321</epage><pages>1306-1321</pages><issn>2575-9108</issn><eissn>2575-9108</eissn><abstract>Nonselective antagonists of muscarinic acetylcholine receptors (mAChRs) that broadly inhibit all five mAChR subtypes provide an efficacious treatment for some movement disorders, including Parkinson's disease and dystonia. Despite their efficacy in these and other central nervous system disorders, antimuscarinic therapy has limited utility due to severe adverse effects that often limit their tolerability by patients. Recent advances in understanding the roles that each mAChR subtype plays in disease pathology suggest that highly selective ligands for individual subtypes may underlie the antiparkinsonian and antidystonic efficacy observed with the use of nonselective antimuscarinic therapeutics. Our recent work has indicated that the M muscarinic acetylcholine receptor has several important roles in opposing aberrant neurotransmitter release, intracellular signaling pathways, and brain circuits associated with movement disorders. This raises the possibility that selective antagonists of M may recapitulate the efficacy of nonselective antimuscarinic therapeutics and may decrease or eliminate the adverse effects associated with these drugs. However, this has not been directly tested due to lack of selective antagonists of M . Here, we utilize genetic mAChR knockout animals in combination with nonselective mAChR antagonists to confirm that the M receptor activation is required for the locomotor-stimulating and antiparkinsonian efficacy in rodent models. We also report the synthesis, discovery, and characterization of the first-in-class selective M antagonists VU6013720, VU6021302, and VU6021625 and confirm that these optimized compounds have antiparkinsonian and antidystonic efficacy in pharmacological and genetic models of movement disorders.</abstract><cop>United States</cop><pmid>34423268</pmid><doi>10.1021/acsptsci.0c00162</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-8023-1313</orcidid><orcidid>https://orcid.org/0000-0003-0168-1445</orcidid><orcidid>https://orcid.org/0000-0002-5225-354X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2575-9108
ispartof ACS pharmacology & translational science, 2021-08, Vol.4 (4), p.1306-1321
issn 2575-9108
2575-9108
language eng
recordid cdi_crossref_primary_10_1021_acsptsci_0c00162
source PubMed Central; American Chemical Society Journals
title Discovery of the First Selective M 4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A26%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20the%20First%20Selective%20M%204%20Muscarinic%20Acetylcholine%20Receptor%20Antagonists%20with%20in%20Vivo%20Antiparkinsonian%20and%20Antidystonic%20Efficacy&rft.jtitle=ACS%20pharmacology%20&%20translational%20science&rft.au=Moehle,%20Mark%20S&rft.date=2021-08-13&rft.volume=4&rft.issue=4&rft.spage=1306&rft.epage=1321&rft.pages=1306-1321&rft.issn=2575-9108&rft.eissn=2575-9108&rft_id=info:doi/10.1021/acsptsci.0c00162&rft_dat=%3Cpubmed_cross%3E34423268%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34423268&rfr_iscdi=true